ArticleThe Journal of clinical investigation2019

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Shaikamjad Umesalma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.